|
Frank
Sams-Dodd, Ph.D., D.Sc.
Publication
list (papers)
1. Dodd, F. and Capranica, R.R. (1992). A comparison of anesthetic
agents and their effects on the response properties of the
peripheral auditory system. Hearing Research, vol. 62, pp.
173-180.
2. Dodd, F.
(1993) Neural networks in pharmacology: Models of mental disorders
and the effects of drug treatments. Nordic Journal of Psychiatry
Supplementum, vol. 47, pp. 17-26.
3. Sams-Dodd,
F. and Capranica, R.R. (1994) Representation of Acoustic Signals
in the Eighth Nerve of the Tokay Gecko: I. Pure Tones. Hearing
Research, vol. 76, pp. 16-30.
4. Sams-Dodd,
F. (1995) Distinct effects of d-amphetamine and phencyclidine on
the social behaviour of rats. Behavioural Pharmacology, vol. 6,
pp. 55-65.
5. Sams-Dodd,
F. (1995) Automation of the social interaction test by a video
tracking system: Behavioural effects of repeated phencyclidine
treatment. Journal of Neuroscience Methods, vol. 59, pp. 157-167.
6. Sams-Dodd,
F. (1996) Phencyclidine-induced stereotyped behaviour and social
isolation in rats: A possible animal model of schizophrenia.
Behavioural Pharmacology, vol. 7, pp. 3-23.
7. Sams-Dodd,
F. and Capranica, R.R. (1996) Representation of Acoustic Signals
in the Eighth Nerve of the Tokay Gecko: II. Masking of Pure Tones
with White Noise. Hearing Research, vol. 100, pp. 131-142.
8. Sams-Dodd,
F. and Newman, J.D. (1997) Effects of administration regime on the
psychotomimetic properties of d-amphetamine in the squirrel monkey
(Saimiri sciureus). Pharmacology Biochemistry and
Behavior, vol. 56, pp. 471-480.
9. Andersen,
M.B. and Sams-Dodd, F. (1997) Transient cerebral ischemia inhibits
juvenile recognition in the mongolian gerbil. Pharmacology,
Biochemistry and Behavior, vol. 56, pp. 719-725.
10. Sams-Dodd,
F. (1997) The effects of novel antipsychotic drugs on PCP-induced
stereotyped behaviour and social isolation in the rat social
interaction test. Behavioural Pharmacology, vol. 8, pp. 196-215.
11. Sams-Dodd,
F., Lipska, B.K. and Weinberger, D.K. (1997) Neonatal lesions of
the rat ventral hippocampus result in hyperlocomotion and deficits
in the social behaviour in adulthood. Psychopharmacology, vol 132,
pp. 303-311.
12. Karle, J.,
Laudrup, P., Sams-Dodd, F., Mikkelsen, J. D. and Nielsen, M.
(1997) Differential changes in seizure behaviour of rats following
hippocampal antisense knockout of the GABAA receptor g2
subunit. European Journal of Pharmacology, vol 340, pp. 153-160.
13. Andersen,
M.B., Zimmer, J. and Sams-Dodd, F. (1997) Post-ischemic
hyperactivity in the mongolian gerbil correlates to loss of
pyramidal cells in the hippocampal CA subfields. Behavioural
Neuroscience, vol. 111, pp. 1205-1216.
14. Sams-Dodd,
F. (1998) The effects of dopamine agonists and antagonists on
PCP-induced stereotyped behaviour and social isolation in rats.
Psychopharmacology, vol. 135, pp. 182-193.
15. Sams-Dodd,
F. (1998) A test of the predictive validity of animal models of
schizophrenia based on phencyclidine and d-amphetamine.
Neuropsychopharmacology, vol. 18, pp. 293-304.
16. Andersen,
M.B. and Sams-Dodd, F. (1998) Impairment of working memory in the
T-maze after transient cerebral ischemia in the mongolian gerbil.
Behavioural Brain Research, vol. 91, pp. 15-22.
17. Sams-Dodd,
F. (1998) Effects of continuous d-amphetamine or phencyclidine
administration on social behaviour, stereotyped behaviour and
locomotor activity in rats. Neuropsychopharmacology, vol. 19,
pp.18-25.
18. Sams-Dodd,
F. (1998) Effects of diazepam, citalopram, methadone and naloxone
on PCP-induced stereotyped behaviour and social isolation in the
rat social interaction test. Neuroscience and Biobehavioural
Reviews, vol. 23, pp. 287-293.
19. Andersen,
M.B., Zimmer, J. and Sams-Dodd, F. (1999) Specific behavioural
effects related to age and cerebral ischemia rats. Pharmacology,
Biochemistry and Behavior, vol. 62, pp. 673-82.
20. Sams-Dodd,
F. (1999) Phencyclidine in the social interaction test: An animal
model of schizophrenia
with face and
predictive validity. Reviews in the Neurosciences, vol. 10, pp.
59-90.
21. Ellenbroek,
B.A., Sams-Dodd, F., and Cools, A.R. (2000) Simulation models for
schizophrenia. In: Atypical antipsychotics, eds. B.A. Ellenbroek &
A.R. Cools, Birkhauser Verlag, Basel, pp. 121-142.
22.
Sams-Dodd, F.
(2004) (+)
MK-801 and Phencyclidine Induced Neurotoxicity do Not Cause
Enduring Behaviours Resembling the Positive and Negative Symptoms
of Schizophrenia in the Rat.
Basic & Clinical Pharmacology & Toxicology, vol.
95, pp. 241-246.
23. Sams-Dodd, F.
(2005) Target-based drug discovery: Is something wrong? Drug
Discovery Today, vol. 10 (2), pp. 139-147.
24. Sams-Dodd, F.
(2005) Optimising the Discovery Organisation for Innovation. Drug
Discovery Today, vol. 10 (15), pp. 1049-1056.
25. Sams-Dodd, F.
(2006) Strategies to optimize the validity of disease models in
the drug discovery process. Drug Discovery Today, vol. 11(7/8),
pp. 355-363.
26. Sams-Dodd, F.
(2006) Drug Discovery: Selecting the Optimal Approach. Drug
Discovery Today, vol. 11 (9/10), pp. 465-472.
27. Larsen, M.H.,
Rosenbrock, H., Sams-Dodd, F. and Mikkelsen, J.D. (2007)
Expression of brain derived neurotrophic factor (BDNF),
activity-regulated cytoskeleton protein (Arc) mRNA, and
enhancement of adult hippocampal neurogenesis in rats after
sub-chronic and chronic treatment with the triple monoamine
re-uptake inhibitor tesofensine (NS2330). European Journal of
Pharmacology, vol. 555, pp. 115-121.
28. Koros, E.,
Rosenbrock, H., Weiss, C. and Sams-Dodd, F. (2007) The selective
mGlu5 receptor antagonist MTEP, similar to NMDA receptor
antagonists, induces social isolation in rats.
Neuropsychopharmacology, vol. 32 (3), pp. 562-576
29. Sams-Dodd,
F. (2007) Research & Market Strategy: How Choice of Drug Discovery
Approach can affect Market Position. Drug Discovery Today, vol. 12
(7/8), pp. 314-318.
|
|
Patents
1. Sams-Dodd, F. and Arnt, J. (1998) Treatment of
schizophrenia and psychosis. International Application no.
PCT/DK98/00220.
2. Bornemann, K., Trummlitz, G., Beck, B., Sams-Dodd, F.,
Kugler, D., Klinder, K., Dorner-Ciossek, C. and Kostka, M. (2005)
Method of treating diseases and conditions associated with an
altered level of amyloid beta peptides and new enolcarboxamide
compounds. EP 04011894.5, USPA 20050277635
3. Bornemann, K., Trummlitz, G., Lazer, ES, Miao, C.K., Beck,
B., Sams-Dodd, F., Kugler, D., Klinder, K., Dorner-Ciossek, C.,
Kostka, M. (2006) Method of treating diseases and conditions
associated with an altered level of amyloid beta peptides and new
enolcarboxamide compounds. USPA 20060040928 |